ZA962711B - Use of imidazol[1,2-a]pyridine-3-acetamide derivatives for the therapeutic treatment of neuropsychiatric syndromes associated with dysfunction of the neural circuits of the basal ganglia - Google Patents

Use of imidazol[1,2-a]pyridine-3-acetamide derivatives for the therapeutic treatment of neuropsychiatric syndromes associated with dysfunction of the neural circuits of the basal ganglia

Info

Publication number
ZA962711B
ZA962711B ZA962711A ZA962711A ZA962711B ZA 962711 B ZA962711 B ZA 962711B ZA 962711 A ZA962711 A ZA 962711A ZA 962711 A ZA962711 A ZA 962711A ZA 962711 B ZA962711 B ZA 962711B
Authority
ZA
South Africa
Prior art keywords
imidazol
dysfunction
pyridine
therapeutic treatment
basal ganglia
Prior art date
Application number
ZA962711A
Other languages
English (en)
Inventor
Elena Benincasa
Original Assignee
Elena Benincasa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elena Benincasa filed Critical Elena Benincasa
Publication of ZA962711B publication Critical patent/ZA962711B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ZA962711A 1995-04-07 1996-04-04 Use of imidazol[1,2-a]pyridine-3-acetamide derivatives for the therapeutic treatment of neuropsychiatric syndromes associated with dysfunction of the neural circuits of the basal ganglia ZA962711B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT95RM000223A IT1276522B1 (it) 1995-04-07 1995-04-07 Uso dello zolpidem per il trattamento terapeudico di sindromi neuropsichiatriche associate a disfunsione e di circuiti neurali dei

Publications (1)

Publication Number Publication Date
ZA962711B true ZA962711B (en) 1996-07-30

Family

ID=11403250

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA962711A ZA962711B (en) 1995-04-07 1996-04-04 Use of imidazol[1,2-a]pyridine-3-acetamide derivatives for the therapeutic treatment of neuropsychiatric syndromes associated with dysfunction of the neural circuits of the basal ganglia

Country Status (25)

Country Link
US (1) US5891891A (hu)
EP (1) EP0819002B1 (hu)
JP (1) JP4049390B2 (hu)
KR (1) KR100425628B1 (hu)
CN (1) CN1198612C (hu)
AR (1) AR003414A1 (hu)
AT (1) ATE222763T1 (hu)
AU (1) AU707759B2 (hu)
CA (1) CA2217590C (hu)
CZ (1) CZ292020B6 (hu)
DE (1) DE69623271T2 (hu)
DK (1) DK0819002T3 (hu)
EA (1) EA000396B1 (hu)
ES (1) ES2182967T3 (hu)
HU (1) HUP9900733A3 (hu)
IL (1) IL117824A (hu)
IT (1) IT1276522B1 (hu)
MX (1) MX9707712A (hu)
NO (1) NO315408B1 (hu)
NZ (1) NZ304107A (hu)
PL (1) PL322647A1 (hu)
PT (1) PT819002E (hu)
TW (1) TW450816B (hu)
WO (1) WO1996031210A1 (hu)
ZA (1) ZA962711B (hu)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7632517B2 (en) * 1997-10-01 2009-12-15 Novadel Pharma Inc. Buccal, polar and non-polar spray containing zolpidem
US6333345B1 (en) 1999-05-14 2001-12-25 Sepracor, Inc. Methods of using and compositions comprising N-desmethylzolpidem
US6399621B1 (en) 1999-08-10 2002-06-04 American Cyanamid Company N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1, 5-α]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto
US20030091632A1 (en) * 1999-08-26 2003-05-15 Neurocrine Biosciences, Inc. Controlled-release sedative-hypnotic compositions and methods related thereto
US6485746B1 (en) 2000-08-25 2002-11-26 Neurocrine Biosciences, Inc. Controlled-release sedative-hypnotic compositions and methods related thereto
US6384221B1 (en) 1999-09-02 2002-05-07 Neurocrine Biosciences, Inc. Polymorphs of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-α]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto
AU5066101A (en) * 2000-04-13 2001-10-30 Synthon B.V. Modified release formulations containing a hypnotic agent
ATE335481T1 (de) * 2000-04-24 2006-09-15 Teva Pharma Zolpidem hemitartrat solvat
DE10041478A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
DE10117183A1 (de) * 2001-04-05 2002-10-10 Gruenenthal Gmbh Verwendung von substituierten Imidazo[1,2-a]-pyridinverbindungen als Arzneimittel
GB0311457D0 (en) * 2003-05-19 2003-06-25 Sciencom Ltd New therapeutic use
KR20060023129A (ko) 2003-05-19 2006-03-13 사이언콤 리미티드 졸피뎀의 추가 치료적 사용
DE10334187A1 (de) * 2003-07-26 2005-03-03 Schwarz Pharma Ag Substituierte 2-Aminotetraline zur Behandlung von Depressionen
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
DK1691811T3 (da) 2003-12-11 2014-10-20 Sunovion Pharmaceuticals Inc Kombination af et sedativ og en neurotransmittermodulator og fremgangsmåder til forbedring af søvnkvaliteten og behandling af depression
DE10361258A1 (de) 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
WO2005079851A2 (en) 2004-02-18 2005-09-01 Sepracor, Inc. Dopamine-agonist combination therapy with sedatives for improving sleep quality
DE102004014841B4 (de) * 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
DE602006008339D1 (en) * 2005-11-18 2009-09-17 Synhton B V Zolpidemtabletten
WO2008056139A2 (en) * 2006-11-08 2008-05-15 Regen Therapeutics Plc Transdermal therapy
GB0809936D0 (en) * 2008-05-30 2008-07-09 Regen Therapeutics Plc Therapeutic use of zolpidem
US11547706B2 (en) 2016-06-08 2023-01-10 President And Fellows Of Harvard College Methods and compositions for reducing tactile dysfunction and anxiety associated with autism spectrum disorder, Rett syndrome, and Fragile X syndrome
AU2019279858A1 (en) 2018-05-29 2020-11-26 President And Fellows Of Harvard College Compositions and methods for reducing tactile dysfunction, anxiety, and social impairment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2492382A1 (fr) * 1980-10-22 1982-04-23 Synthelabo Derives d'imidazo (1,2-a) pyridine, leur preparation et leur application en therapeutique
US5032595A (en) * 1989-11-24 1991-07-16 Fidia-Georgetown Institute For The Neurosciences Method of stimulating steroidogenesis with alpidem
US5206382A (en) * 1991-06-27 1993-04-27 Fidia Georgetown Institute For The Neurosciences Indole derivatives, pharmaceutical compositions and methods of treating neurological and psychiatric disorders

Also Published As

Publication number Publication date
EP0819002B1 (en) 2002-08-28
DE69623271T2 (de) 2003-07-24
AR003414A1 (es) 1998-08-05
ATE222763T1 (de) 2002-09-15
EA000396B1 (ru) 1999-06-24
NO974603L (no) 1997-11-24
CZ316797A3 (cs) 1998-05-13
KR100425628B1 (ko) 2004-06-23
JP4049390B2 (ja) 2008-02-20
DE69623271D1 (de) 2002-10-02
HUP9900733A2 (hu) 1999-07-28
CZ292020B6 (cs) 2003-07-16
NO974603D0 (no) 1997-10-06
NZ304107A (en) 2000-12-22
DK0819002T3 (da) 2003-01-06
NO315408B1 (no) 2003-09-01
ITRM950223A0 (it) 1995-04-07
PL322647A1 (en) 1998-02-16
IT1276522B1 (it) 1997-10-31
PT819002E (pt) 2003-01-31
ES2182967T3 (es) 2003-03-16
MX9707712A (es) 1998-03-31
AU707759B2 (en) 1999-07-22
EP0819002A1 (en) 1998-01-21
CN1198612C (zh) 2005-04-27
CN1183719A (zh) 1998-06-03
IL117824A (en) 2000-08-31
IL117824A0 (en) 1996-08-04
ITRM950223A1 (it) 1996-10-07
US5891891A (en) 1999-04-06
HUP9900733A3 (en) 2003-05-28
EA199700308A1 (ru) 1998-04-30
TW450816B (en) 2001-08-21
WO1996031210A1 (en) 1996-10-10
KR19980703707A (ko) 1998-12-05
CA2217590C (en) 2008-08-12
CA2217590A1 (en) 1996-10-10
JPH11503149A (ja) 1999-03-23
AU5120096A (en) 1996-10-23

Similar Documents

Publication Publication Date Title
ZA962711B (en) Use of imidazol[1,2-a]pyridine-3-acetamide derivatives for the therapeutic treatment of neuropsychiatric syndromes associated with dysfunction of the neural circuits of the basal ganglia
PL322623A1 (en) Derivatives of imidazo [1,2-a] pyridine
ZA928832B (en) Local delivery of dipyridamole for the treatment of proliferative diseases
IL133800A0 (en) Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
HU9401317D0 (en) Antiviral 2-ethyl - 1h imidazo (4,5-c) quinolin-4-amines
GB2305605B (en) Pipecolic acid derivatives for the treatment of neurological disorders
EP0524946A4 (en) Treatment of central nervous system disorders with imidazole angiotensin-ii receptor antagonists
FI92401B (fi) Menetelmä valmistaa farmakologisesti arvokasta pyrrolo/3,2,1-jk//1,4/bentsodiatsepiinijohdannaista
EP1027054A4 (en) LOCAL CONTRIBUTION OF PHOSPHODIESTERASE INHIBITORS IN THE TREATMENT OF ERECTILE DYSFUNCTION
HK1040905B (zh) 噠嗪並(4，5-b)吲哚-1-乙酰胺衍生物在製備用於治療與周圍神經受體苯並二氮雜䓬的失調有關的疾病的藥物中的用途
IL92078A0 (en) Use of bicyclic imidazole compounds for the treatment of hyperaldosteronism
HK1036274A1 (en) Imidazo (1,2-a) pyridine derivatives for the treatment of gastrointestinal diseases
EP0577023A3 (en) Angiotensin-ii receptor-antagonists for the treatment of arrhythmices
EP0554098A3 (en) Process for the preparation of imidazo 4,5-b pyridine derivatives
HUP9901258A3 (en) Imidazo[2,1-b]thiazole and thiazolo[3,2-a]pyrimidine derivatives, process for the preparation thereof, their use and pharmaceutical compositions containing them
EP0436831A3 (en) Imidazo(1,2-a)pyridinylalkyl compounds for treatment of neurotoxic injury
FI98816B (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten 4,5,6,7-tetrahydroimidatso [4,5,1-jk][1,4]bentsodiatsepin-2-oni ja -2-tionijohdannaisten valmistamiseksi
ZA893606B (en) Use of diazepinones for treating disorders of the microcirculation
AU595776B3 (en) Therapeutic device for male sexual dysfunction
ZA985818B (en) Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders.
ZA886511B (en) Pyrrolo(1,2-a)imidazole and imidazo(1,2-a)pyridine derivatives and their use as 5-lipoxygenase pathway inhibitors
ZA937604B (en) 3,3-disubstituted tri and tetracyclic indolin-2-ones useful for the treatment of cognitive disorders
IE893261L (en) PYRROLO (1,2-a) IMIDAZOLES AND IMIDAZO (1,2-a) PYRIDINES
BG96767A (en) Method for the preparation of an antitumour medicament
CS397691A3 (en) Pyrrolo(1,2-a)imidazole and pyrrolo(1,2-a)pyridine derivatives and theiruse as 5-lipoxygenase pathway inhibitors